Overview

A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine

Status:
Completed

Trial end date:
2015-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of sirukumab as a single therapy in Japanese patients with moderately to severely active rheumatoid arthritis (RA) who have not responded to treatment with methotrexate (MTX) or sulfasalazine (SSZ).

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Pharmaceutical K.K.

Collaborator:

GlaxoSmithKline

Treatments:

Antibodies, Monoclonal
Methotrexate
Sulfasalazine